AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

医学 溃疡性结肠炎 安慰剂 临床终点 氨基水杨酸 内科学 意向治疗分析 耐受性 临床试验 胃肠病学 外科
作者
Katsuyoshi Matsuoka,Mamoru Watanabe,Toshihide Ohmori,Koichi Nakajima,Tetsuya Ishida,Yoh Ishiguro,Kazunari Kanke,Kiyonori Kobayashi,Fumihito Hirai,Kenji Watanabe,Hidehiro Mizusawa,Shuji Kishida,Yoshiharu Miura,Akira Ohta,Toshifumi Kajioka,Toshifumi Hibi
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
标识
DOI:10.1016/s2468-1253(22)00022-x
摘要

Summary

Background

AJM300 is an oral, small-molecule α4-integrin antagonist. We assessed the efficacy and safety of AJM300 in patients with moderately active ulcerative colitis.

Methods

This multicentre, randomised, double-blind, placebo-controlled, phase 3 study consisted of two phases: a treatment phase and an open-label re-treatment phase. The study was done at 82 hospitals and clinics in Japan. Patients with a Mayo Clinic score of 6–10, endoscopic subscore of 2 or more, rectal bleeding subscore of 1 or more, and an inadequate response or intolerance to mesalazine were enrolled. Patients were randomly allocated (1:1) via a website to either AJM300 (960 mg) or placebo by the minimisation method, which was adjusted centrally by dynamic assignment against the Mayo Clinic score (≥6 to ≤7, ≥8 to ≤10 points), any use of corticosteroid, anti-TNFα antibody, or immunosuppressants during the disease-active period (yes vs no), duration of induction therapy until randomisation (<4 weeks vs ≥4 weeks) as the minimisation factors. Patients, investigators, site staff, assessors, and the sponsor were masked to treatment assignments. The study drug was administered orally, three times daily, for 8 weeks, and continued for up to 24 weeks if endoscopic remission was not achieved or rectal bleeding did not stop. The primary endpoint was the proportion of patients with a clinical response at week 8, and was analysed in the full analysis set. Clinical response was defined as a reduction in Mayo Clinic score of 30% or more and 3 or more, a reduction in rectal bleeding score of 1 or more or rectal bleeding subscore of 1 or less, and an endoscopic subscore of 1 or less at week 8. The study is registered with ClinicalTrials.gov, NCT03531892, and is closed to recruitment.

Findings

Between June 6, 2018, and July 22, 2020, 203 patients were randomly assigned to AJM300 (n=102) or placebo (n=101). At week 8, 46 (45%) patients in the AJM300 group and 21 (21%) patients in the placebo group had a clinical response (odds ratio 3·30, 95% CI 1·73−6·29; p=0·00028). During the 8-week treatment and 16-week extension treatment periods, adverse events occurred in 39 (39%) of 101 patients in the placebo group and 39 (38%) of 102 patients in the AJM300 group. We found no difference in the incidence of adverse events between groups or after repeated administration of AJM300. The most common adverse event was nasopharyngitis (11 [11%] of 101 patients in the placebo group and ten [10%] of 102 patients in the AJM300 group). The most common treatment-related adverse event was also nasopharyngitis (four [4%] of 101 patients in the placebo group and three [3%] of 102 patients in the AJM300 group). Most adverse events were mild-to-moderate in severity. No deaths were reported. A serious adverse event was reported in the AJM300 group (one patient with anal abscess), but this was judged to be unrelated to study drug.

Interpretation

AJM300 was well tolerated and induced a clinical response in patients with moderately active ulcerative colitis who had an inadequate response or intolerance to mesalazine. AJM300 could be a novel induction therapy for the treatment of patients with moderately active ulcerative colitis.

Funding

EA Pharma and Kissei Pharmaceutical.

Translation

For the Japanese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
幽默的问梅完成签到,获得积分10
刚刚
刚刚
刚刚
酷波er的应助被阿业采纳,获得10
1秒前
1秒前
大模型的应助被wyc采纳,获得10
1秒前
无问西东给WYL的求助进行了留言
2秒前
拼搏一曲完成签到,获得积分10
2秒前
顺利毕业发布了新的文献求助10
2秒前
ggb发布了新的文献求助10
2秒前
TT完成签到,获得积分10
3秒前
姜海绵发布了新的文献求助10
3秒前
3秒前
3秒前
thisky发布了新的文献求助30
3秒前
秋风的应助被老迟到的越泽采纳,获得20
4秒前
4秒前
Ray发布了新的文献求助10
5秒前
5秒前
小荀完成签到,获得积分10
5秒前
5秒前
今后的应助被qin202569采纳,获得10
6秒前
6秒前
6秒前
7秒前
风吹麦浪的应助被Chen采纳,获得10
7秒前
renpp822发布了新的文献求助10
7秒前
无花果的应助被corleeang采纳,获得10
8秒前
情怀的应助被lee采纳,获得10
8秒前
8秒前
8秒前
1097发布了新的文献求助10
9秒前
9秒前
9秒前
张建秀发布了新的文献求助30
9秒前
10秒前
小吉完成签到,获得积分10
10秒前
10秒前
11秒前
鱿鱼的云朵完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124